Alprostadil

Pharmacologic Category

Prostaglandin; Vasodilator

Dosing: Adult

Erectile dysfunction:

Intracavernous (Caverject, Caverject Impulse, Edex): Individualize dose by careful titration; doses >40 mcg (Edex) or >60 mcg (Caverject) are not recommended: Initial dose must be titrated in health care provider setting. Patient must stay in the health care setting until complete detumescence occurs; if there is no response, then the next higher dose may be given within 1 hour; if there is still no response, a 1-day interval before giving the next dose is recommended; doses should be titrated to the lowest effective dose; increasing the dose or concentration in the treatment of impotence results in increasing pain and discomfort.

Initial dose titration: According to the prescribing information for Caverject and Caverject Impulse, no more than 2 doses should be given within a 24-hour period during the initial titration.

Vasculogenic, psychogenic, or mixed etiology: Initiate dosage titration at 2.5 mcg.

If there is a partial response, increase dose by 2.5 mcg to a dose of 5 mcg and then, in increments of 5 to 10 mcg (depending on erectile response) until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached.

If there is no response to the initial 2.5 mcg dose, the second dose may be increased to 7.5 mcg and administered within 1 hour, followed by increments of 5 to 10 mcg (Edex).

If there is a response, then there should be at least a 24-hour interval before the next dose is given.

Neurogenic etiology (eg, spinal cord injury): Note: Caverject powder must be used to prepare a 1.25 mcg dose: Initiate dosage titration at 1.25 mcg; if there is a partial response, may increase to a dose of 2.5 mcg within 1 hour and if necessary, to a dose of 5 mcg; may increase further in increments of 5 mcg until the dose is reached that produces an erection suitable for intercourse and not exceeding a duration of 1 hour.

Maintenance: Once an appropriate dose has been determined, patient may self-administer injections at a frequency of no more than 3 times/week with at least 24 hours between doses

Intraurethral (Muse Pellet):

Initial: 125 to 250 mcg; dose may be increased or decreased on separate occasions in a stepwise manner until the patient achieves an erection that is sufficient for sexual intercourse.

Maintenance: Administer as needed to achieve an erection; duration of action is about 30 to 60 minutes; use only two systems per 24-hour period.

Raynaud phenomenon (off-label use): IV: 60 mcg over 3 hours once daily for 5 or 6 consecutive days followed by maintenance dosing of 60 mcg over 3 hours once every 30 days (Bartolone 1999; Marasini 2004) or 40 mcg (at a rate of 3 to 5 ng/kg/minute) twice daily for ≥7 days and repeated every 3 to 4 weeks (Lamprecht 1998).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Use lowest effective dose. In clinical studies with Edex, higher minimally effective doses and a higher rate of lack of effect were noted. Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

Ductus arteriosus patency, maintenance: Infants: Continuous IV infusion: Initial: 0.05 to 0.1 mcg/kg/minute; once therapeutic response is achieved, reduce rate to lowest effective dosage; with unsatisfactory response, increase rate gradually; usual maintenance: 0.01 to 0.4 mcg/kg/minute. Note: Therapeutic response is indicated by an increase in systemic blood pressure and pH in those with restricted systemic blood flow and acidosis, or by an increase in oxygenation (pO2) in those with restricted pulmonary blood flow.

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Calculations

• REVEAL PAH Score

Use: Labeled Indications

Patent ductus arteriosus (Prostin VR Pediatric): Temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed. These defects include cyanotic (eg, pulmonary atresia, pulmonary stenosis, tricuspid atresia, Fallot's tetralogy, transposition of the great vessels) and acyanotic (eg, interruption of aortic arch, coarctation of aorta, hypoplastic left ventricle) heart disease.

Erectile dysfunction:

Caverject, Edex, Caverject Impulse: Treatment of erectile dysfunction due to vasculogenic, psychogenic, neurogenic, or mixed etiology; Caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction

Muse: Treatment of erectile dysfunction

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Raynaud phenomenonLevel of Evidence [C, G]

Data from a limited number of patients studied suggest that alprostadil may be beneficial for the treatment of secondary Raynaud phenomenon Ref.

Based on the European League Against Rheumatism guidelines for the treatment of systemic sclerosis, IV prostanoids are recommended in severe Raynaud phenomenon associated with systemic sclerosis or when first-line oral therapies have failed Ref. Access Full Off-Label Monograph

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Erectile Dysfunction:

AUA, “Erectile Dysfunction,” 2018

Systemic Sclerosis:

EULAR, "Update of EULAR Recommendations for the Treatment of Systemic Sclerosis," August 2017

Usual Infusion Concentrations: Pediatric

IV infusion: 10 mcg/mL or 20 mcg/mL

Administration: Other

Intraurethral: Erectile dysfunction

Muse: Insert immediately after urination. Prior to insertion, remove the product from the foil pouch and remove the protective cover from the applicator stem; ensure medicated pellet is present. While sitting or standing, slowly stretch the penis upward to its full length, with gentle compression from top to bottom of the glans. Slowly insert the Muse stem into the urethra up to the collar. Gently press down on the button at the top of the applicator until it stops; leave applicator in place for 5 seconds. Gently rock the applicator from side to side then remove the applicator while keeping the penis upright. If there is residual medication at the end of the applicator, reinsert the applicator and repeat prior steps. Once the applicator is removed, hold the penis upright and stretched to its full length, and roll firmly between hands for at least 10 seconds. Standing or walking for about 10 minutes after administration will increase blood flow and enhance erection.

Administration: Intracavernous

Erectile dysfunction:

Caverject: Wipe the intended injection site with an alcohol swab prior to injection. Use a 1/2 inch, 29- or 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes after administration.

Caverject Impulse: Supplied as a disposable, single-dose, dual chamber syringe system. Wipe the intended injection site with an alcohol swab prior to injection. After attaching the provided needle assembly, select dose and inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes after administration.

Edex: Wipe the intended injection site with an alcohol swab prior to injection. Use a 1/2 inch, 27- to 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Administer over a 5- to 10-second interval. Compress the site of injection with an alcohol swab for 5 minutes after administration.

Administration: Pediatric

Continuous IV infusion: Administer into a large vein or alternatively through an umbilical artery catheter placed at the ductal opening.

Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by concentration (mcg/mL)

Storage/Stability

Caverject Impulse: Store unreconstituted product at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Following reconstitution, store at 2°C to 25°C (36°F to 77°F) and use within 24 hours (do not freeze). Discard any unused solution.

Caverject powder: Store 20 mcg vials at 20°C to 25°C (68°F to 77°F). Store 40 mcg vials at 2°C to 8°C (36°F to 46°F) until dispensed. After dispensing, stable for up to 3 months at or below 25°C (77°F). Following reconstitution, all strengths should be stored at or below 25°C (77°F); do not refrigerate or freeze; use within 24 hours.

Edex: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Muse: Store at 2°C to 8°C (36°F to 46°F); may be stored at room temperature (below 30°C [86°F]) for up to 14 days. Do not expose to temperatures >30°C (86°F). Each system is for single use only; discarded after use.

Prostin VR Pediatric: Refrigerate at 2°C to 8°C (36°F to 46°F). Extended storage information at room temperature may be available; contact product manufacturer to obtain current recommendations.

Preparation for Administration: Adult

Caverject Impulse: Provided as a dual-chamber syringe with diluent in one chamber. To mix, hold syringe with needle pointing upward and rotate plunger clockwise until it goes all the way in and stops (do not push on the plunger while trying to rotate it); turn upside down several times to evenly mix solution. Device can be set to deliver specified dose, each device can be set at various increments.

Caverject powder: Use only the supplied diluent for reconstitution (ie, bacteriostatic/sterile water with benzyl alcohol 0.945%).

Edex: Reconstitute with NS; use immediately following reconstitution. Discard any remaining solution in cartridge.

Preparation for Administration: Pediatric

Continuous IV infusion: Prostin VR Pediatric: Dilute with D5W, D10W, or NS to a maximum concentration of 20 mcg/mL per the manufacturer. ISMP and Vermont Oxford Network recommend a standard concentration of 10 mcg/mL for neonates (ISMP 2011). Avoid direct contact of undiluted alprostadil with the plastic walls of volumetric infusion chambers because the drug will interact with the plastic and create a hazy solution; discard solution and volumetric chamber if this occurs.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat erectile dysfunction (ED).

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Urethra warming or burning

• Aching in penis or surrounding area

• Penile pain

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Severe penile pain

• Erectile redness, lumps, swelling, or curving

• Injection site irritation

• Chest pain

• Fast heartbeat

• Dizziness

• Passing out

• Severe headache

• Shortness of breath

• Bruising

• Bleeding

• Swelling of leg veins

• Erection that lasts more than 4 hours

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Intracavernous: Hypersensitivity to alprostadil or any component of the formulation; conditions predisposing men to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia); men with anatomical deformation or fibrotic conditions of the penis (eg, angulation, cavernosal fibrosis, or Peyronie disease); penile implants

IV: There are no contraindications listed in the US labeling.

Canadian labeling: Cyanotic neonates with persistent circulation; neonates with total anomalous pulmonary venous return below the diaphragm; neonates with polysplenia or asplenia in whom pulmonary atresia is combined with anomalous pulmonary venous return, which may be obstructed

Transurethral: Hypersensitivity to alprostadil or any component of the formulation; urethral stricture, balanitis, severe hypospadias and curvature, and in men with acute or chronic urethritis; men who are prone to venous thrombosis or who have a hyperviscosity syndrome (eg, sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma) predisposing them to priapism; use in men for whom sexual activity is inadvisable; sexual intercourse with a pregnant woman unless a condom barrier is being used

Documentation of allergenic cross-reactivity for prostaglandins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Apnea: [US Boxed Warning]: Prostin VR Pediatric: Apnea may occur in 10% to 12% of neonates with congenital heart defects, especially in those weighing <2 kg at birth. Apnea usually appears during the first hour of drug infusion.

• Hypotension/syncope: Intracavernous injections can increase peripheral blood levels of alprostadil, resulting in hypotension. Syncope has also been reported. Avoid use in men with known cavernosal venous leakage. Patients must be cautioned to avoid tasks such as operating machinery or driving following administration where injury could result if hypotension or syncope were to occur.

• Penile fibrosis: May occur when used for erectile dysfunction; discontinue use in men who develop penile angulation or cavernosal fibrosis.

• Priapism/prolonged erection: May occur when used for erectile dysfunction; instruct patient to seek immediate medical assistance if an erection persists ≥4 hours; discontinue therapy if priapism or prolonged erection occurs or if signs of penile fibrosis develop (penile angulation, cavernosal fibrosis, or Peyronie disease). To minimize the chances of prolonged erection or priapism, titrate slowly to the lowest effective dose. Use is contraindicated in men who have conditions that predispose them to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia). Underlying causes of erectile dysfunction should be evaluated and treated prior to therapy.

Disease related concerns:

• Cardiovascular disease: Treatment for erectile dysfunction should not be used in men whom sexual activity is inadvisable because of underlying cardiovascular status.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Neonates: Prostin VR Pediatric: Use with caution in neonates with bleeding tendencies.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

Other warnings/precautions:

• Administration: Muse: Urethral abrasion resulting in minor bleeding or spotting may occur from improper administration.

• Needle breakage: Caverject and Caverject Impulse: A superfine needle is used for administration. Needle breakage (a portion of the needle remaining in the penis) has been reported; hospitalization and surgical removal may be necessary.

• Patency of ductus arteriosus: Appropriate use: Prostin VR Pediatric: Infuse for the shortest time at the lowest dose consistent with good patient care. Use for >120 hours has been associated with antral hyperplasia and gastric outlet obstruction.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Elderly may have concomitant diseases which would contraindicate the use of alprostadil. Other forms of attaining penile tumescence are recommended.

Warnings: Additional Pediatric Considerations

Alprostadil should not be used in neonates with respiratory distress syndrome; full diagnostic workup should be done to differentiate between respiratory distress syndrome and cyanotic heart disease. Cortical proliferation of long bones has been associated with long-term infusions of alprostadil; most cases of bone changes occurred 4 to 6 weeks after starting alprostadil, but has occurred as early as 9 days. In a study of 86 infants awaiting cardiac transplant, the incidence of hyperostosis was 42% at <30 days of alprostadil infusion, 87% at 30 to 60 days and 100% at >60 days. Cortical hyperostosis usually resolves over 6 to 12 months after stopping alprostadil (Kaufman 1996; Woo 1994).

Reproductive Considerations

Muse is contraindicated in males having sexual intercourse with a pregnant woman unless a condom barrier is being used.

Pregnancy Considerations

Alprostadil is not indicated for use in women.

Breast-Feeding Considerations

Alprostadil is not indicated for use in women.

Adverse Reactions

Intraurethral:

>10%: Genitourinary: Penile pain, urethral burning

2% to 10%:

Central nervous system: Dizziness, headache, pain

Genitourinary: Testicular pain, urethral bleeding (minor), vulvovaginal pruritus (female partner)

<2%: Leg pain, perineal pain, tachycardia

Intracavernosal injection:

>10%: Genitourinary: Penile pain

1% to 10%:

Cardiovascular: Hypertension

Central nervous system: Dizziness, headache

Genitourinary: Prolonged erection (>4 hours, 4%), penile disease, penile rash, penile swelling, Peyronie's disease

Local: Bruising at injection site, hematoma at injection site

<1%: Balanitis, injection site hemorrhage, priapism (0.4%)

Intravenous:

>10%:

Cardiovascular: Flushing

Respiratory: Apnea

Miscellaneous: Fever

1% to 10%:

Cardiovascular: Bradycardia, cardiac arrest, edema, hypertension, hypotension, tachycardia

Central nervous system: Dizziness, headache, seizure

Endocrine & metabolic: Hypokalemia

Gastrointestinal: Diarrhea

Hematologic & oncologic: Disseminated intravascular coagulation

Infection: Sepsis

Local: Local pain (in structures other than the injection site)

Neuromuscular & skeletal: Back pain

Respiratory: Cough, flu-like symptoms, nasal congestion, sinusitis, upper respiratory tract infection

<1%: Anemia, anuria, bradypnea, cardiac failure, cerebral hemorrhage, gastroesophageal reflux disease, hematuria, hemorrhage, hyperbilirubinemia, hyperemia, hyperirritability, hyperkalemia, hypoglycemia, hypothermia, jitteriness, lethargy, neck hyperextension, peritonitis, second degree atrioventricular block, shock, stiffness, supraventricular tachycardia, thrombocytopenia, ventricular fibrillation, wheezing (bronchial)

* See Cautions in AHFS Essentials for additional information.

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of Alprostadil. Risk X: Avoid combination

Monitoring Parameters

Blood pressure, respiratory rate, heart rate, temperature, degree of penile pain, duration of erection, adequate detumescence after dosing, signs of infection, signs of penile fibrosis

Advanced Practitioners Physical Assessment/Monitoring

Neonate: Assess patient closely for apnea during first hour after administration. Erectile dysfunction: Determine individualized dose. Assess for history of priapism.

Nursing Physical Assessment/Monitoring

Neonate: Monitor patient closely for apnea during first hour after administration. Erectile dysfunction: Teach patient appropriate injection technique and syringe/needle disposal. Educate about need for emergency care for erection lasting longer than 4 hours. Caution patient about rapid change in position, especially within an hour of administration; can cause dizziness.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Kit, Intracavernosal:

Caverject Impulse: 10 mcg, 20 mcg [contains benzyl alcohol, lactose]

Edex: 10 mcg, 20 mcg, 40 mcg [pyrogen free; contains lactose]

Pellet, Urethral:

Muse: 125 mcg (1 ea, 6 ea); 250 mcg (1 ea, 6 ea); 500 mcg (1 ea, 6 ea); 1000 mcg (1 ea, 6 ea)

Solution, Injection:

Prostin VR: 500 mcg/mL (1 mL) [contains alcohol, usp]

Generic: 500 mcg/mL (1 mL)

Solution Reconstituted, Intracavernosal:

Caverject: 20 mcg (1 ea)

Caverject: 40 mcg (1 ea) [contains benzyl alcohol, lactose]

Solution Reconstituted, Intracavernosal [preservative free]:

Caverject: 20 mcg (1 ea [DSC]) [contains lactose]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Kit, Intracavernosal:

Caverject: 20 mcg [contains benzyl alcohol, lactose]

Pellet, Urethral:

Muse: 250 mcg (1 ea); 500 mcg (1 ea); 1000 mcg (1 ea)

Solution, Injection:

Prostin VR: 500 mcg/mL (1 mL) [contains alcohol, usp]

Generic: 500 mcg/mL (1 mL)

Solution Reconstituted, Intracavernosal:

Caverject: 20 mcg (1 ea) [contains lactose]

Anatomic Therapeutic Chemical (ATC) Classification

• C01EA01
• G04BE01

Generic Available (US)

May be product dependent

Pricing: US

Kit (Caverject Impulse Intracavernosal)

10 mcg (per each): $92.49

20 mcg (per each): $119.11

Kit (Edex Intracavernosal)

10 mcg (per each): $162.08

20 mcg (per each): $209.39

40 mcg (per each): $285.94

Pellet (Muse Urethral)

125 mcg (per each): $74.42

250 mcg (per each): $77.89

500 mcg (per each): $83.35

1000 mcg (per each): $90.01

Solution (Alprostadil Injection)

500 mcg/mL (per mL): $130.01

Solution (Prostin VR Injection)

500 mcg/mL (per mL): $155.66

Solution (reconstituted) (Caverject Intracavernosal)

40 mcg (per each): $155.90

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Causes vasodilation by means of direct effect on vascular and ductus arteriosus smooth muscle; relaxes trabecular smooth muscle by dilation of cavernosal arteries when injected along the penile shaft, allowing blood flow to and entrapment in the lacunar spaces of the penis (ie, corporeal veno-occlusive mechanism)

Pharmacodynamics/Kinetics

Onset of action: Erectile dysfunction: 5 to 20 minutes

Duration: Ductus arteriosus will begin to close within 1 to 2 hours after drug is stopped; Erectile dysfunction: Intended duration <1 hour

Distribution: Insignificant following penile injection

Protein binding, plasma: 81% to albumin

Metabolism: IV: ~70% to 80% by oxidation during a single pass through the lungs; metabolite (13,14 dihydro-PGE1) is active and has been identified in neonates

Half-life elimination: 30 seconds to 10 minutes

Time to peak:

Acyanotic congenital heart disease: Usual: 1.5 to 3 hours; Range: 15 minutes to 11 hours.

Cyanotic congenital heart disease: Usual: ~30 minutes

Erectile dysfunction: Intracavernosal 30 to 60 minutes; Transurethral: ~16 minutes

Excretion: Primarily urine (90% as metabolites) within 24 hours; feces

Pharmacodynamics/Kinetics: Additional Considerations

Pulmonary disease: May have reduced capacity to clear the drug.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Index Terms

Alprostadil Alfadex; PGE1; Prostaglandin E1

FDA Approval Date

July 06, 1995

References

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Bartolone S, Trifiletti A, De Nuzzo G, et al. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon. Minerva Cardioangiol. 1999;47(5):137-143.[PubMed 10479851]

Browning Carmo KA, Barr P, West M, et al, "Transporting Newborn Infants With Suspected Duct Dependent Congenital Heart Disease on Low-Dose Prostaglandin E1 Without Routine Mechanical Ventilation," Arch Dis Child Fetal Neonatal Ed, 2007, 92(2):F117-9.[PubMed 16905574]

Caverject (alprostadil) [prescribing information]. New York, NY: Pfizer Inc; December 2017.

Caverject Impulse (alprostadil) [prescribing information]. New York, NY: Pfizer Inc; October 2016.

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol-United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Cohen V, Jellinek SP, Teperikidis L, et al, “Room-Temperature Storage of Medications Labeled for Refrigeration,” Am J Health-Syst Pharm, 2007, 64(16):1711-15.[PubMed 17687059]

Edex (alprostadil) [prescribing information]. Lake Forest, IL: Actient Pharmaceuticals; August 2018.

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf

Kaufman MB and El-Chaar GM, “Bone and Tissue Changes Following Prostaglandin Therapy in Neonates,” Ann Pharmacother, 1996, 30(3):269-74, 277.[PubMed 8833563]

Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909[PubMed 27941129]

Lamprecht P, Schnabel A, Gross WL. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon. Br J Rheumatol. 1998;37(6):703-704.[PubMed 9667634]

Lewis AB, Freed MD, Heymann MA, et al, “Side Effects of Therapy With Prostaglandin E1 in Infants With Critical Congenital Heart Disease,” Circulation, 1981, 64(5):893-8.[PubMed 7285304]

Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. Scand J Rheumatol. 2004;33(4):253-256.[PubMed 15370722]

Muse (alprostadil) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; April 2018.

Peled N, Dagan O, Babyn P, et al, “Gastric-Outlet Obstruction Induced by Prostaglandin Therapy in Neonates,” N Engl J Med, 1992, 327(8):505-10.[PubMed 1635565]

Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” Am J Health Syst Pharm, 2011, 68(22):2176-82.[PubMed 22058104]

Prostin VR (alprostadil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; April 2019.

Prostin VR Pediatric (alprostadil injection) [prescribing information]. New York, NY: Pfizer Injectables; April 2013.

Prostin VR Pediatric (alprostadil) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; July 2014.

Stone DM, Frattarelli DA, Karthikeyan S, et al, "Altered Prostaglandin E1 Dosage During Extracorporeal Membrane Oxygenation in a Newborn With Ductal-Dependent Congenital Heart Disease," Pediatr Cardiol, 2006, 27(3):360-3.[PubMed 16565906]

Weesner KM, “Hemodynamic Effects of Prostaglandin E1 in Patients With Congenital Heart Disease and Pulmonary Hypertension,” Cathet Cardiovasc Diagn, 1991, 24(1):10-5.[PubMed 1913785]

Williams G, Abbou CC, Amar ET, et al, “The Effect of Transurethral Alprostadil on the Quality of Life of Men With Erectile Dysfunction, and Their Partners. MUSE Study Group,” Br J Urol, 1998, 82(6):847-54.[PubMed 9883223]

Woo K, Emery J, and Peabody J, “Cortical Hyperostosis: A Complication of Prolonged Prostaglandin Infusion in Infants Awaiting Cardiac Transplantation,” Pediatrics, 1994, 93(3):417-20.[PubMed 8115200]

Brand Names: International

Alfaprostin (EG); Alostin (KR); Alprospire (EG); Alprostan (RU, UA); Alprostapint (BG, HU); Caverject (AE, AR, AT, BB, BH, BM, BO, BR, BS, BZ, CL, CO, CR, CY, DE, DO, EC, EE, ES, FR, GB, GT, GY, HU, IE, IQ, IR, IS, JM, JO, KR, KW, LB, LU, LV, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PR, PT, PY, QA, SA, SE, SG, SI, SR, SV, SY, TR, TT, TW, UY, VE, VN, YE, ZA); Caverject Dual Chamber (FR, HK); Caverject Impulse (AU); Caverjet (IL); Edex (FR); Eglandin (KR); Gaverject (PK); Liple (JP); Minprog (AT); Muse (AE, BE, BH, CY, ES, GB, IE, IQ, IR, JO, LT, LV, LY, OM, QA, SA, SY, YE, ZA); Palux (JP); Pridax (RO); Prink (KR); Promostan (TW); Prostandin (JP, KR); Prostavasin (AE, AR, BR, CN, CR, CY, DO, EG, GT, HN, HU, JO, LU, MX, NI, PA, PH, SK, SV, UY); Prostin Pediatrico (CL); Prostin VR (AE, AU, BE, BH, CH, CO, CY, GB, GR, HN, HR, HU, IL, IN, IQ, IR, IT, JO, LB, LU, LY, NL, NZ, OM, PL, QA, SA, SY, TH, TW, YE, ZA); Prostin VR Paedeatric (MY); Prostin VR Pediatric (HK); Prostine VR (FR); Prostivas (DK, FI, NO, SE); Vazostenon (UA); Viridal (DE, IE); Virilan (AT); Vitaros (CR, DO, GB, GT, HN, IE, NI, PA, SV); Vitaros Cream (LB); Vytaros (BE)

Last Updated 4/28/20